Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 14.0-74.0,  Diabetes Mellitus, Type 1 Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year 2. Use of an insulin pump for at least 6 months with established parameters for basal rate(s), carbohydrate ratio(s) and insulin sensitivity factor(s) for at least 3 months. 3. Age 14.0 to <75.0 years 4. HbA1c level <10.5% at screening 5. For females, not currently known to be pregnant. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study. Also, subjects who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued. 6. Have care partner committed to participating in all training activities, knowledgeable at all times of the participants location, and being present and available to provide assistance when the system is being used at night 7. Willingness, if using the closed-loop system, to stop closed-loop when taking acetaminophen and avoid closed-loop for at least 4 hours afterward 8. Willingness to suspend use of any personal CGM for the duration of the clinical trial once the study CGM is in use 9. Willingness to establish network connectivity on a daily basis either via local Wi-Fi network or via a study-provided cellular service 10. Investigator has confidence that the subject can successfully operate all study devices and is capable of adhering to the protocol 11. Currently using no insulins other than one of the following rapid-acting insulins at the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin glulisine (Apidra) 12. Total daily insulin dose (TDD) less than 100 U/day  More than one episode of diabetic ketoacidosis (DKA) in the 6 months prior to enrollment 2. More than one episode of severe hypoglycemia involving seizure of loss of consciousness in the 6 months prior to enrollment 3. Medical need for chronic acetaminophen 4. Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals). 5. Hemophilia or any other bleeding disorder 6. A condition, which in the opinion of the investigator or designee, would put the participant or study at risk 7. Participation in another pharmaceutical or device trial at the time of enrollment or during the study 8. Employed by, or having immediate family members employed by TypeZero Technologies, LLC